Szpital Wojewodzki W Opolu Sp. z o.o. — Clinical Trial Site

16 Registered trials

8 Currently recruiting

Organisation

Szpital Wojewodzki W Opolu Sp. z o.o.

Location

Opole, Poland

Identifier

ORG-100048905

Address

Ul. Katowicka 64, 45-061, Poland

Departments

#8002; Oddzial Kliniczny Hematologii, Onkologii Hematologicznej i Chorob Wewnetrznych
161603: Oddzial Kliniczny Hematologii, Onkologii Hematologicznej i Chorob Wewnetrznych
Department of Hematology, Hematological Oncology and Internal Medicine
Oddzial Hematologii i Onkologii Hematologicznej
Oddzial Kliniczny Hematologii, Onkologii Hematologicznej i Chorob Wewnetrznych
Oddział Kliniczny Hematologii, Onkologii Hematologicznej i Chorób Wewnętrznych

Clinical trials at this site (16)

Search interface

Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting

2025-522669-32-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-12-18
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Relapsed or Refractory B-Cell Malignancies 9 2025-10-15
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi… Recruiting

2023-507396-21-00 transfusion-dependent α- or β-thalassemia or low-risk m 4 2023-03-16
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19
PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Recruiting

2024-518454-17-00 relapsed/refractory hematologic malignancies 1 2021-01-08
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-… Ended

2023-506871-88-00 Relapsed/Refractory Multiple Myeloma 3 2022-10-07
A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Diffuse large B-cell lymphoma 5 2020-11-23
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
Extended Access of Momelotinib for Subjects with Myelofibrosis Ended

2023-508018-41-00 Primary Myelofibrosis (PMF), Post-polycythemia Vera or 4 2018-07-27
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi… Ended

2023-509348-84-00 Chronic Lymphocytic Leukemia 5 2015-04-27
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablurs… Ended

2024-512482-14-00 Polycythemia Vera 4 2023-06-21
Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansi… Ended

2024-516691-14-00 B Cell Malignancies and Chronic Lymphocytic Leukemia or 7 2021-01-05
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch… Ended

2023-507498-16-00 Diffuse Large B-Cell Lymphoma (DLBCL) 9 2019-07-02